Mr. Robert Andrade reports

FENNEC PHARMACEUTICALS TO REPORT FULL YEAR AND FOURTH QUARTER 2025 FINANCIAL RESULTS ON MARCH 24, 2026

Fennec Pharmaceuticals Inc. will release its full year and fourth quarter 2025 financial results before the opening of the United States financial markets on Tuesday, March 24, 2026. Management will host a conference call and webcast that day to discuss the company's financial and business results.

Conference call and webcast detail:

Date:  Tuesday, March 24, 2026

Time:   8:30 a.m. Eastern Time

To access the live webcast link, log onto the Fennec website, and proceed to the news and events/event calendar page under the investors and media heading. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on the company's website for 30 days.

About Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of Pedmark to reduce the risk of platinum-induced ototoxicity in cancer patients. Pedmark received Food and Drug Administration approval in September, 2022, and European Commission approval in June, 2023, and United Kingdom (U.K.) approval in October, 2023, under the brand name Pedmarqsi.

In March, 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize Pedmarqsi in Europe, U.K., Australia and New Zealand. Pedmarqsi is now commercially available in the U.K. and Germany.

Pedmark has received Orphan Drug Exclusivity in the U.S. and Pedmarqsi has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for Pedmark until 2039 in both the U.S. and internationally.